These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16517208)

  • 21. Developing treatment for sickle cell disease.
    Steinberg MH; Brugnara C
    Expert Opin Investig Drugs; 2002 May; 11(5):645-59. PubMed ID: 11996646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent.
    Sullivan KJ; Goodwin SR; Evangelist J; Moore RD; Mehta P
    Crit Care Med; 1999 Nov; 27(11):2563-8. PubMed ID: 10579281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.
    Gladwin MT; Kato GJ
    Hematology Am Soc Hematol Educ Program; 2005; ():51-7. PubMed ID: 16304359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Priapism in sickle-cell disease: a hematologist's perspective.
    Kato GJ
    J Sex Med; 2012 Jan; 9(1):70-8. PubMed ID: 21554552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.
    Rother RP; Bell L; Hillmen P; Gladwin MT
    JAMA; 2005 Apr; 293(13):1653-62. PubMed ID: 15811985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sickle red cell microrheology and sickle blood rheology.
    Ballas SK; Mohandas N
    Microcirculation; 2004 Mar; 11(2):209-25. PubMed ID: 15280093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine.
    Hebbel RP
    Am J Hematol; 2011 Feb; 86(2):123-54. PubMed ID: 21264896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravascular hemolysis and the pathophysiology of sickle cell disease.
    Kato GJ; Steinberg MH; Gladwin MT
    J Clin Invest; 2017 Mar; 127(3):750-760. PubMed ID: 28248201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.
    Kato GJ; Gladwin MT; Steinberg MH
    Blood Rev; 2007 Jan; 21(1):37-47. PubMed ID: 17084951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity.
    Gladwin MT; Schechter AN; Shelhamer JH; Pannell LK; Conway DA; Hrinczenko BW; Nichols JS; Pease-Fye ME; Noguchi CT; Rodgers GP; Ognibene FP
    J Clin Invest; 1999 Oct; 104(7):937-45. PubMed ID: 10510334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation.
    Gladwin MT; Crawford JH; Patel RP
    Free Radic Biol Med; 2004 Mar; 36(6):707-17. PubMed ID: 14990351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathophysiology of sickle cell anemia.
    Bookchin RM; Lew VL
    Hematol Oncol Clin North Am; 1996 Dec; 10(6):1241-53. PubMed ID: 8956013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The perfusion paradox and vascular instability in sickle cell disease.
    Nath KA; Katusic ZS; Gladwin MT
    Microcirculation; 2004 Mar; 11(2):179-93. PubMed ID: 15280091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy.
    Reiter CD; Gladwin MT
    Curr Opin Hematol; 2003 Mar; 10(2):99-107. PubMed ID: 12579034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pathophysiological consequences of hemolysis. Role of cell-free hemoglobin].
    Misztal T; Tomasiak M
    Postepy Hig Med Dosw (Online); 2011 Sep; 65():627-39. PubMed ID: 22100795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasculopathy and pulmonary hypertension in sickle cell disease.
    Potoka KP; Gladwin MT
    Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L314-24. PubMed ID: 25398989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What are the most promising emerging therapies for sickle cell disease?
    Ferreira de Melo TR; Chin CM; dos Santos JL
    Future Med Chem; 2014 Jun; 6(9):979-82. PubMed ID: 25068981
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pathophysiology of sickle cell disease].
    Elion J; Laurance S; Lapouméroulie C
    Med Trop (Mars); 2010 Dec; 70(5-6):454-8. PubMed ID: 21520646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the red blood cell in nitric oxide homeostasis and hypoxic vasodilation.
    Gladwin MT
    Adv Exp Med Biol; 2006; 588():189-205. PubMed ID: 17089890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.